Royalty and licensing income	9 Months Ended
Apr. 30, 2016
Royalty And Licensing Income [Abstract]
Royalty And Licensing Income [Text Block]	Note 11 – Royalty and licensing income The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the nine months ended April 30, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $1.1 million and $2.1 million respectively, which is included in the Life Sciences segment.

Royalty and licensing income

9 Months Ended

Apr. 30, 2016

Royalty And Licensing Income [Abstract]

Royalty And Licensing Income [Text Block]

Note 11 – Royalty and licensing income

The Company’s Life Science segment has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the nine months ended April 30, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $1.1 million and $2.1 million respectively, which is included in the Life Sciences segment.